Jim Tananbaum Gigantic Investment Bets in the Health Sector

Jim Tananbaum, the founder, chief executive officer and managing director of Foresite Capital have welcomed Dr.Molly, a former senior director at Illumina, to the company as a venture partner. Foresite Company is San Francisco-based healthcare growth firm that aims at conducting extensive researches on medical and drugs breakthrough. This is done by providing capital and expertise to anchor public and private healthcare facilities to research and help their products get approved for use and sale to the public. More details can be found on Crunchbase.

Having a more than 25 years’ expertise in healthcare entrepreneurship and investment, Jim has acknowledged Dr.Molly as a precious asset to company’s breakthroughs. Having attained B.A in Biochemistry from Nankai University and a Ph.D. In protein biophysics from the University of California, Dr. Molly has vast experience in drug development and genomics. In addition, he had spent valuable years in the pharmaceutical industry and is an Author of various published medical work. You can visit LinkedIn to know more.

Holding a B.S.E.E from Yale University, an MD from Harvard Medical School, an MS from MIT and an MD and MBA from Harvard University, Jim Tananbaum, is a guru in healthcare investments. In his early career, he co-founded Prospect and Sierra Ventures where he helped instill investment practice in healthcare services. He attributes franchising to adopting strategic, operational and financial opportunities in the health care facilities. His major reputed led investments include Amira, Amerigroup, Jazz and Healtheon pharmaceuticals to mention a few. This has led to Jim ranked number 52 in Forbes magazine 2017 Mida List, of the 100 Top Tech Ventures Capital Investors, for the third consecutive year.

Despite founding Foresite in 2011, Jim Tananbaum also founded and headed Theravance Inc. and GelTex Pharmaceuticals, which brought two drugs to the market for less than $80 million and today they generate over $1 billion in revenue. Through Nanostring Technologies Inc., the company is providing a range of apparatus on help in medical and diagnostics applications research projects. Its current investment companies include Orexigen, Therapeauticals Inc., Bio Delivery Sciences International Inc., among others. According to the stock market, Foresite has an approximate of $650 million worth of assets under its management. Visit Foresite Capital LinkedIn.

The 44 years old Manhattan-born billionaire, is also a Member of Yale’s University Council and the advisory committee of the Yale School of Engineering & Applied Science.

Check out his Facebook page